Global study finds heart failure drug spironolactone fails to lower cardiovascular risk in dialysis patients

Global study finds heart failure drug spironolactone fails to lower cardiovascular risk in dialysis patients

A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving dialysis, despite earlier smaller studies suggesting benefit.

Global Study Finds Heart Failure Drug Spironolactone Fails to Lower Cardiovascular Risk in Dialysis Patients

A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving dialysis, despite earlier smaller studies suggesting benefit.

Study Finds Spironolactone Ineffective in Reducing Cardiovascular Deaths or Hospitalizations for Dialysis Patients

A recent global study has determined that spironolacton […] The post Study Finds Spironolactone Ineffective in Reducing Cardiovascular Deaths or Hospitalizations for Dialysis Patients first appeared on GeneOnline News. The post Study Finds Spironolactone Ineffective in Reducing Cardiovascular Deaths or Hospitalizations for Dialysis Patients appeared first on GeneOnline News.